Astrazeneca PLC (NYSE:AZN) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday. The firm currently has a $36.15 target price on the stock. Vetr‘s price objective would indicate a potential upside of 6.89% from the company’s previous close.
AZN has been the subject of several other reports. Bank of America Corp. set a $41.40 target price on shares of Astrazeneca PLC and gave the company a “buy” rating in a research note on Thursday, September 8th. Argus upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research report on Monday, August 29th. Berenberg Bank restated a “buy” rating on shares of Astrazeneca PLC in a research report on Sunday, September 11th. Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a research report on Friday, August 26th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Astrazeneca PLC in a research report on Thursday, July 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $37.49.
Astrazeneca PLC (NYSE:AZN) traded up 0.48% during trading on Monday, reaching $33.82. 5,154,736 shares of the company traded hands. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The firm has a 50-day moving average price of $33.40 and a 200-day moving average price of $30.24. The company has a market capitalization of $85.56 billion, a P/E ratio of 38.65 and a beta of 0.77.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/astrazeneca-plc-azn-raised-to-strong-buy-at-vetr-inc.html
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The firm earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. During the same period in the previous year, the business posted $1.21 EPS. The business’s revenue was down 4.0% compared to the same quarter last year. Analysts forecast that Astrazeneca PLC will post $2.97 earnings per share for the current fiscal year.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were given a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio is presently 78.29%.
Several hedge funds have recently modified their holdings of the company. Dodge & Cox boosted its stake in shares of Astrazeneca PLC by 121.2% in the first quarter. Dodge & Cox now owns 26,049,650 shares of the company’s stock valued at $733,558,000 after buying an additional 14,272,518 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock valued at $368,453,000 after buying an additional 12,095,375 shares in the last quarter. Capital International Investors boosted its stake in shares of Astrazeneca PLC by 22.1% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company’s stock valued at $618,094,000 after buying an additional 3,705,199 shares in the last quarter. BlackRock Investment Management LLC boosted its stake in shares of Astrazeneca PLC by 73.2% in the second quarter. BlackRock Investment Management LLC now owns 7,207,036 shares of the company’s stock valued at $217,580,000 after buying an additional 3,046,268 shares in the last quarter. Finally, Becker Capital Management Inc. acquired a new stake in shares of Astrazeneca PLC during the second quarter valued at about $35,701,000. 11.71% of the stock is currently owned by institutional investors and hedge funds.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Astrazeneca PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astrazeneca PLC and related companies with MarketBeat.com’s FREE daily email newsletter.